Original contributionB7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer

- B7-H4 may play an important promoter role in the process of pancreatic cancer.
- B7-H4 was associated with TNM stage, distant metastasis, and differentiation.
- B7-H4 was an independent predictor of poor prognosis in pancreatic cancer.

SummaryB7-H4 belongs to the immune costimulatory B7 family and is thought to negatively regulate T-cell-mediated immunity, and may contribute an important role in tumor immune evasion. Although the expression of B7-H4 has been observed in human pancreatic cancer, the prognostic significance of this expression is poorly understood. This present study explored the prognostic value of B7-H4 in pancreatic cancer. Patients with pancreatic cancer and healthy controls were recruited at the Second Affiliated Hospital to Zhejiang University from January 2011 to December 2014. Expression of B7-H4 was assessed by immunohistochemistry. Immunohistochemical analysis indicated that B7-H4 was expressed in 100% (188/188) of the pancreatic cancer tumor tissue samples, while only in 68% (17/25) of normal pancreatic tissue samples. Furthermore, the expression levels of B7-H4 in pancreatic cancer patients were significantly higher than in controls (P < .01). A significant difference in B7-H4 expression was observed between patients with late tumor-node-metastasis (TNM) stage (III and IV) and early TNM stage (I and II) (P < .01). The expression of B7-H4 was associated with distant metastasis (P < .01) and differentiation (P < .01). In addition, B7-H4 expression (P < .01), distant metastasis (P < .01), TNM stage (P < .01), differentiation (P < .01) and chemotherapy treatment (P < .05) were indicators of poor overall survival time. Multivariate survival analysis indicated that B7-H4 expression, distant metastasis, and chemotherapy treatment (P < .05) were independent prognostic indicators of poor overall survival. In conclusion, B7-H4 is highly expressed in pancreatic cancer, and is an independent predictor of poor prognosis in patients with pancreatic cancer. B7-H4 may represent an immunotherapeutic target in pancreatic cancer.